Abivax (ABVX) Other Non-Current Liabilities (2023 - 2026)
Abivax (ABVX) posted quarterly Other Non-Current Liabilities of $21.2 million for Q1 2026, up 1843.46% year-over-year from $1.1 million in Q1 2025, and down 36.81% quarter-over-quarter from $33.6 million in Q4 2025.
Abivax (ABVX) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Abivax's Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $21.2 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 1843.46% year-over-year to $21.2 million; the TTM figure through Mar 2026 stood at $21.2 million (up 1843.46% YoY), while the FY2025 annual figure was $33.6 million, up 1864.11% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $21.2 million, down from $33.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $33.6 million in Q4 2025, with the low at $29076.0 in Q2 2024.
- The 4-year median for Other Non-Current Liabilities is $1.6 million (2024), against an average of $9.8 million.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities soared 5196.93% in 2024, then soared 1843.46% in 2026.
- Abivax's Other Non-Current Liabilities stood at $32278.2 in 2023, then jumped by 5196.93% to $1.7 million in 2024, then jumped by 1864.11% to $33.6 million in 2025, then slumped by 36.81% to $21.2 million in 2026.
- Business Quant data shows ABVX's Other Non-Current Liabilities at $21.2 million in Q1 2026, $33.6 million in Q4 2025, and $19.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.22 Mn |
| Dec 31, 2025 | 33.58 Mn |
| Sep 30, 2025 | 19.43 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Jun 30, 2024 | 29,075.96 |
| Dec 31, 2023 | 32,278.20 |